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Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, UK
Scope: Numerous studies feeding anthocyanin-rich foods report limited bioavailability of the
parent anthocyanins. The present study explores the identity and concentration of the phenolic
metabolites of anthocyanins in humans.
Methods and results: Anthocyanin metabolites were quantified in samples collected from a
previously conducted 12-wk elderberry intervention study in healthy post-menopausal women.
Individual 1-, 2- and 3-h post-bolus urine samples and pooled plasma samples following acute
(single bolus) and chronic (12-wk supplementation) anthocyanin consumption (500 mg/day)
were analysed usingHPLC-ESI-MS/MS. Twenty-eight anthocyaninmetabolites were identified
in urine and 21 in plasma (including sulfates of vanillic, protocatechuic and benzoic acid).
Phenolic metabolites reached peak concentrations of 1237 nM in plasma, while anthocyanin
conjugates only reached concentrations of 34 nM. Similarly, in urine, phenolicmetabolites were
detected at concentrations of 33 185 ± 2549 nM/mM creatinine, while anthocyanin conjugates
reached concentrations of 548 ± 219 nM/mM creatinine. There was no evidence that chronic
exposure had any impact on either the profile or quantity of metabolites recovered relative to
acute exposure.
Conclusion: Anextensive range of phenolicmetabolites of anthocyaninwas identified following
elderberry consumption in humans, including 11 novel metabolites, which were identified at
much higher concentrations than their parent compounds.
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1 Introduction
A number of epidemiological [1–3] and in vitro [4, 5] stud-
ies have linked high consumption of anthocyanin-rich foods
with a reduced risk of cardiovascular disease. However, am-
biguity has arisen concerning the absorption, distribution,
metabolism and elimination of anthocyanins, as their recov-
ery from biological samples has been poor, with studies rarely
identifying above 1% of the ingested dose [6–8]. This raises
questions regarding the metabolic fate of anthocyanins and
similarly the compounds/metabolites responsible for their
potential cardioprotective effects.
Correspondence: Dr. Colin D. Kay, Department of Nutrition, Nor-
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UK
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Abbreviations: C3G, cyanidin-3-glucoside; P3G, peonidin-3-
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PFP, pentafluorophenol; VA, vanillic acid
Due to their unstable nature, significant quantities of
anthocyanins are unlikely to be present in the circula-
tion in their parent forms [9]. The degradation of antho-
cyanins to their phenolic acid and aldehyde constituents
has been well established in vitro [10, 11]; yet few human
studies have detected these degradation products within
biological samples [12]. Human intervention studies feed-
ing anthocyanin-rich foods and extracts including cranberry,
strawberry and bilberry-loganberry have identified potential
metabolites of anthocyanins including hippuric acid, benzoic
acid, 4-hydroxybenzoic acid, protocatechuic acid (PCA), dihy-
droxybenzoic acids, caffeic acid, p-courmaric acid, ferulic acid,
sinapic acid, 2-hydroxyphenylacetic acid, homovanillic acid,
vanillic acid (VA) and 4-hydroxyphenylacetic acid [13–17].
Our recent study feeding a pure 13C-labeled anthocyanin
(500 mg) to human volunteers confirmed many of these
structures, in addition to identifying novel metabolites; 25
individual 13C-labeled phenolic metabolites were recovered,
attaining a total peak concentration of 5.97 ± 2.14 M in the
serum and 10.77 ± 4.52 M in the urine [18]. The present
study aimed to confirm the formation of these anthocyanin-
derived metabolites following the consumption of an
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anthocyanin-rich dietary source (elderberries; Sambucus
nigra), as opposed to a pure synthetic anthocyanin prepa-
ration. We used stored samples from a previously com-
pleted 12-wk anthocyanin intervention, where healthy post-
menopausal women were fed 500 mg/day of anthocyanins
derived from 2 g of elderberry extract [19]. The present
study also investigated the impact of a single 500 mg bolus
(acute post-prandial effect) and repeated daily 500 mg doses
(post-prandial effect after 12-wk chronic supplementation)
on metabolite excretion to establish if sustained exposure al-
tered either the quantity or profile of metabolites eliminated.
To the best of our knowledge, this is the first study to describe
the impact of acute versus chronic anthocyanin exposure on
anthocyanin-derived phenolic metabolites.
2 Materials and methods
2.1 Chemicals and materials
Cyanidin-3-glucoside (C3G), peonidin-3-glucoside (P3G) and
cyanidin-3-sambubioside were obtained from Extrasynthese
(Genay, France). Phase II conjugates of phenolic acids
(PCA-3-glucuronide, PCA-4-glucuronide, VA-4-glucuronide,
benzoic acid-4-glucuronide, isoVA-3-glucuronide, isoVA-3-
sulfate, PCA-4-sulfate, VA-4-sulfate, PCA-3-sulfate and ben-
zoic acid-4-sulfate) were synthesised in the School of Chem-
istry and Centre for Biomolecular Sciences, University of
St. Andrews (UK) via recently published methods [20]. All
other metabolites (Fig. 1) were purchase from Sigma-Aldrich
(Dorset, England). Strata-XTM SPE columns (6 mL, 500
mg), Kinetex pentafluorophenol (PFP) HPLC column (2.6
m, 100 × 4.6 mm, 100 A˚) and SecurityGuard R© cartridges
(PFP, 4.0 × 2.0 mm) were purchased from Phenomenex
(UK). HPLC grade methanol, acetonitrile and hydrochloric
acid (HCl) were purchased from Fisher Scientific (Lough-
borough, UK). Discovery R© DSC-18 SPE columns (6 mL,
1 g) and Acrodisc 13 mm, 0.45 m PTFE syringe filters and
all other chemicals were purchased from Sigma-Aldrich. All
water utilised was of Milli-Q grade (18.2 M/cm).
2.2 Analysis of elderberry extract
The anthocyanin content of the elderberry (S. nigra) extract
(standardised to 25% anthocyanins) obtained from Artemis
International (Fort Wayne, Indianapolis, IN, USA) was previ-
ously established as 500mg anthocyanins (C3G and cyanidin-
3-sambubioside, quantified as C3G equivalents) per 2 g ex-
tract [19]. The phenolic profile was presently established
through HPLC-ESI-MS/MS analysis, where prior to analy-
sis, 500 mg of elderberry extract was dissolved in 2 mL of
0.1% HCl and 5 mL acidified methanol (0.1% v/v HCl) and
sonicated for 30 min followed by syringe filtration.
2.3 Study design
We previously conducted a parallel-designed, randomised,
placebo-controlled study feeding elderberry extract or placebo
to 52 (26 in treatment and 26 in placebo group) healthy (age,
58.2 ± 5.6 years; BMI, 24.7 ± 0.6 kg/m2) post-menopausal
women [19], which explored the effect of anthocyanins on
cardiovascular bioactivity and liver function. Participants un-
derwent a 7-day washout period (avoiding anthocyanin-rich
foods and limiting tea and chocolate intake), followed by
the consumption of identically coloured opaque elderberry
or placebo capsules each day for 12 wk. Dietary restric-
tions were continued throughout the duration of the 12-wk
intervention. The elderberry capsules provided a daily total of
2 g elderberry extract, containing 500 mg total anthocyanins
while the placebo capsules contained 500 mg of cellulose.
Participants were assessed following a single bolus dose (wk
0, acute) and following 12 wk of continuous supplementa-
tion (wk 12, chronic), where blood and urine samples were
collected in the fasting period (baseline) and over 3 h follow-
ing the consumption of a 500 mg oral bolus dose of antho-
cyanins. An anthocyanin- and caffeine-free breakfast of ce-
real (WeetabixTM (Weetabix, UK) or Cornflakes (KelloggsTM,
UK)), white toast with margarine/butter, milk and water was
provided ad libitum on the intervention days. Post-prandial
blood and urine samples were collected for 3 h (t = 1, 2,
3 h) following ingestion. Blood was collected in EDTA tubes
and plasma obtained by centrifugation at 1500 × 3 g for
15 min, where urine and plasma samples were acidified with
HCl (to a final concentration of 1%) prior to storage at –80C
until analysis. The study protocol was approved by the Nor-
folk Research Ethics Committee (ClinicalTrials.gov registry
identifier NCT00574574), conducted at the University Clini-
cal Research and Trials Unit (UEA, UK) and all participants
provided written informed consent. In the present investiga-
tion, a random subset of the banked samples from 15 of the
26 participants on the anthocyanin treatment was analysed to
explore the effect of 12-wk repeated dosing on anthocyanin
metabolism (the placebo group was not explored).
2.4 Creatinine analysis
Urine creatinine concentrations were quantified on an iLab
650 Chemistry Analyzer using the IL Test Creatinine-
0018257240 kit (Instrumentation Laboratory, Italy). Quality
control samples indicated a CV = 4.24%, n = 6.
2.5 Sample preparation
Urine and plasma samples were extracted using precondi-
tioned DSC-18 (for urine) and Strata-XTM (for plasma) SPE
cartridges, evaporated to approximately 50Lusing aThermo
speedvac and diluted with 200 L of 10% formic acid v/v in
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Figure 1. Structure of anthocyanins, degradation products and putative metabolites. BA, benzoic acid; BAL, benzaldehyde;
GlcA, glucuronide; PCA, protocatechuic acid; PGA, phloroglucinaldehyde; VA, vanillic acid.
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water (pH 2.4). A total of 10 L of 1 mg/mL scopoletin was
added as the volume control standard post-extraction and
samples were then syringe filtered. Individual analysis of the
urine samples was carried out to establish metabolite varia-
tion between participants, while plasma samples were pooled
prior to extraction, by taking 66.7L of plasma from each par-
ticipant (n = 15; for a total volume 1 mL), thus providing a
“snapshot” of the plasma metabolic profile. The extraction
efficiency of the SPE methods for C3G and the 17 phenolic
metabolites identified in urine and plasma was established as
88.0 ± 5.4% (CV, 8.6 ± 5.4%) for urine and 86.9 ± 9.1% (CV,
8.2 ± 5.9%) for plasma, for n = 3 replicates of each analyte.
2.6 HPLC-MS/MS analysis
HPLC-MS/MS analysis was carried out on an Agilent 1200
series HPLC system coupled with an AB Sciex 3200 Q-trap
MS/MS, with samples injected onto a Kinetex PFP column.
The mobile phase consisted of 0.1% formic acid v/v in water
(A) and 0.1% formic acid v/v in acetonitrile (B), at a flow rate of
1.5mL/min at 0min, 1mL/min at 7–14min and 1.5mL/min
at 14–28 min. The gradient consisted of 1% B at 0 min, 7.5%
B at 7 min, 7.6% B at 14 min, 10% B at 17 min, 12% B at
18.5 min, 12.5% B at 20 min, 30% B at 24 min and 90% B
at 25–28 min. MS/MS source parameters included curtain
gas 40 psi, ionspray voltage –4000 V/+5500 V, temperature
700C, nebulizer gas and auxiliary gas 60 psi. The system
was controlled by Analyst software (v. 1.5, Applied Biosys-
tems/MDS Sciex). Multiple reaction monitoring scans were
performed using conditions optimised for the detection of
pure standards (Table 1). Metabolites were confirmed on the
basis of retention time and the presence of two or more ion
transitions. The peak area of the most intense ion transition
was determined from the chromatograph and used for quan-
tification. Seven-point calibration curves ranging from 0 to
10 M for the analysis of the anthocyanin conjugates and
from 0 to 50M for the analysis of phenolic metabolites were
utilised for quantification. The calibration curves were pre-
pared by spiking a standard mixture of the compounds into a
matchedmatrix (pooled blank/baseline urine or plasma from
all participants) and were baseline adjusted to account for any
interference from analytes present in baseline samples, such
as phenolic compounds. For anthocyanin glucuronide and
sulfate conjugates, where the corresponding standards were
not available, compounds were quantified relative to C3G or
P3G (where appropriate).
The HPLC-MS/MS methods were validated for linearity
andprecision across allmetabolites. Six-point standard curves
ranging from 1.25 to 20 M were constructed from analyt-
ical standards and injected six times. The precision was es-
tablished as 1.4–8.2% and linearity of the standard curves
was established as r2 = 0.991–1.000 (CV, 0.2%) across the
identified metabolites. In addition, there was a between run
variation of 9.17% CV for quality control standards injected
between every eight samples run.
2.7 Statistics
All statistical analyses were performed using SPSS for Win-
dows (statistical software package version 18.0). Within-
subject comparisons were analysed using a repeated-
measures general linear model, with Greenhouse-Geisser
correction for non-spherical data and Bonferroni adjustment
(within-subjects, baseline, 0–1 h, 1–2 h, 2–3 h) for pairwise
comparisons. Between-group comparisons were analysed us-
ing repeated-measures general linear model, with Bonfer-
roni adjustment (within-subjects, wk 0 and wk 12 at baseline,
0–1 h, 1–2 h, 2–3 h). Unless otherwise stated, results are
expressed as mean ± SD and p ≤ 0.05 was considered sig-
nificant. Baseline refers to the fasting samples collected prior
to the consumption of the anthocyanin bolus. No statistical
analyses were possible for the pooled plasma samples (n = 1;
15 participants plasma pooled at each individual time point).
3 Results
3.1 Elderberry extract composition
Independent analysis of the commercially available
elderberry-derived anthocyanin extract identified 15 phenolic
acids, aldehydes or benzoates (hereafter referred to as phe-
nolics) present, accounting for 202.90 mg total phenolics per
gram of elderberry extract (Table 2). PCAwas identified in the
highest concentrations, constituting 68.3% of the total phe-
nolics identified, followed by phloroglucinaldehyde (PGA)
(7.7%) and caffeic acid (7.3%). The anthocyanin content of
the elderberry bolus was previously established as 250 mg
anthocyanin per gram extract [19], predominantly consisting
of C3G (53.5%) and cyanidin-3-sambubioside (39.5%) [21].
Elderberries are also reported to contain low amounts of
cyanidin-3-sambubioside-5-glucoside (6%) and cyanidin-3,5-
diglucoside (1%) [21]. A total proximate analysis of the extract
was not conducted to establish the composition of the remain-
ing 55% by weight; however, elderberries have a reported rel-
ative composition of 18.4% carbohydrate, 0.7% protein, 0.5%
fat, 0.5% organic acids and 6.2% quercetin [21–23].
3.2 Metabolites in urine and plasma
Twenty-eight metabolites were identified in the urine fol-
lowing acute anthocyanin consumption, of which 17 were
phenolics and 11 were anthocyanin conjugates (Table 3).
Cumulatively, urinary phenolic metabolite concentrations
were 60-fold higher (ranging from 145 ± 86 to 7382 ±
5927 nM/mMcreatinine at 3-h) than the parent anthocyanins
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Table 1. HPLC-MS/MS parameters for the identification of anthocyanins, anthocyanin conjugates and phenolics in human urine after the
ingestion of 500 mg elderberry anthocyanins
Compound Rt (min) MW Precursor ion/MS2 fragments (m/z) CE (V) DP (V) EP (V) CXP (V)
Anthocyanins
Cyanidin-3-glucoside (C3G) 11.6 449.4 449/287a), 241, 213, 137 +30 +60 +5 +2.5
Cyandin-3-sambubioside 12.0 581.5 581/287a) +60 +30 +5 +2.5
Cyanidin-glucuronide 11.7 463.4 463/287a) +60 +30 +5 +2.5
Cyanidin-glucuronide 16.5 463.4 463/287a) +60 +30 +5 +2.5
C3G-glucoside-disulfate 21.1 609.5 609/287a) +60 +30 +5 +2.5
Cyanidin-diglucuronide 9.3 639.5 639/287a) +60 +30 +5 +2.5
Peonidin-3-glucoside (P3G) 16.9 463.4 463/301a) +60 +30 +5 +2.5
Peonidin-glucuronide 17.0 477.4 477/301a) +60 +30 +5 +2.5
P3G-glucuronide 5.8 639.5 639/301a) +60 +30 +5 +2.5
P3G-glucuronide 8.2 639.5 639/301a) +60 +30 +5 +2.5
P3G-glucuronide 9.4 639.5 639/301a) +60 +30 +5 +2.5
Hydroxybenzoic acids
2-Hydroxybenzoic acid 16.7 138.1 137/93a), 75, 65 −25 −30 −7 −2
3-Hydroxybenzoic acid 8.1 138.1 137/93a), 65 −18 −40 −9.5 0
4-Hydroxybenzoic acid 6.5 138.1 137/93a), 65 −20 −35 −5 0
Protocatechuic acid (PCA) 4.3 154.1 153/108a), 91, 81 −31 −42 −10 0
3,5-Dihydroxybenzoic acid 4.4 154.1 153/109a), 67, 65 −16 −35 −9.5 0
Methoxybenzoic acids
Vanillic acid (VA) 9.4 168.1 167/152a), 123, 108 −20 −30 −2 0
Methyl-3,4-dihydroxybenzoate 12.9 168.1 167/108a), 91 −28 −45 −8 0
4-Methoxysalicyclic acidb) 20.1 168.1 167/123, 108a), 80 −15 −34 −3 −2
Syringic acid 12.1 198.2 199/155, 140a), 125, 77 +21 +34 +5 +6
Cinnamic acids
Caffeic acid 10.4 180.2 179/135a), 106, 89 −20 −45 −6 −2
Sinapic acid 20.6 224.2 223/208a), 193, 164, 149 −18 −38 −2 −2
p-Coumaric acid 15.1 164.2 163/119a), 117, 93 −20 −30 −10 0
Ferulic acid 18.8 194.2 193/178, 149, 134a) −20 −30 −6 −2
Aldehydes
Phloroglucinaldehyde 16 154.1 153/151a), 125, 107, 83 −20 −88 −7 −2
4-Hydroxybenzaldehyde 8.5 122.1 121/108a), 92, 65 −31 −47 −7 −10
3,4-Dihydroxybenzaldehyde 5.8 138.1 137/108a), 92, 81 −30 −40 −10 0
Phenylacetic acids
Homovanillic acid 9.6 182.2 181/137a), 122 −10 −43 −2 −4
Homoprotocatechuic acidc) 4.6 168.1 167/123a), 108, 95 −20 −20 −8 −2
Conjugated metabolites
Benzoic acid-4-glucuronide 3 314.2 313/175, 137, 113, 93a) −54 −54 −7 −2
PCA-3-glucuronide 4.4 330.2 329/175,153a), 113, 109 −25 −45 −5 −3
PCA-4-glucuronide 3.3 330.2 329/175, 153a), 113, 109 −25 −45 −5 −3
VA-4-glucuronide 4.9 344.3 343/175, 167, 152, 113a) −20 −60 −4 −2
IsoVA-3-glucuronide 6.2 344.3 343/175, 167, 152, 113a) −20 −66 −4 −2
Benzoic acid-4-sulfate 7.5 218.2 217/173, 137a) −21 −31 −3 −2
PCA-sulfate 6.3 234.2 233/189, 153, 109a), 97 −30 −38 −3 −2
VA-sulfate 8.8 248.2 247/167a), 152, 123, 108 −20 −33 −4 −2
Benzyl alcohols
4-Hydroxybenzyl alcohol 4.4 124.1 123/105, 77a) −20 −24 −10 −2
Hippuric acids
Hippuric acid 6.3 179.2 178/134a), 132, 77 −18 −40 −3 0
Internal standards
Phloridzin 24.1 436.4 435/273a), 167, 123, 81 −26 −40 −4 −2
Scopoletin 18.4 192.2 191/148, 120, 104a) −34 −35 −10 0
193/133a), 122, 94 +27 +56 +4 +4
A dwell time of 50 ms was used across all transitions.
a) MRM transition used for quantitation.
b) Also commonly known as 3,4-dihydroxyphenylacetic acid.
c) Also commonly known as 2-hydroxy-4-methoxybenzoic acid.
C3G, cyanidin-3-glucoside; CE, collision energy corresponding to parent/daughter fragments used for MRM quantitation; DP, declustering
potential; MW, molecular weight; P3G, peonidin-3-glucoside; PCA, protocatechuic acid; Rt, retention time; VA, vanillic acid; V, Volts.
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Table 2. Phenolics present within 1 g elderberry extract (25% an-
thocyanin content, from Artemis International)
Phenolic compounds Concentration
(mg/g extract)
Protocatechuic acid 138.59 ± 4.48
Phloroglucinaldehyde 15.65 ± 1.18
Caffeic acid 14.74 ± 1.10
4-Hydroxybenzoic acid 11.28 ± 0.28
p-Courmaric acid 9.43 ± 0.32
Vanillic acid 2.70 ± 0.13
4-Hydroxybenzaldehyde 2.51 ± 0.01
Methyl-3,4-dihydroxybenzoate 1.85 ± 0.14
Gallic acid 1.54 ± 1.18
Ferulic acid 1.39 ± 0.08
3,4-Dihydroxybenzaldehyde 1.37 ± 0.02
Sinapic acid 1.10 ± 0.22
Homoprotocatechuic acid 0.38 ± 0.03
Isovanillic acid 0.30 ± 0.01
Methyl gallate 0.04 ± 0.00
Data represented as mean ± SD, n = 3.
(which ranged from0.1± 0.3 to 309± 673nM/mMcreatinine
at 3 h). In plasma, 21 metabolites were identified, of which
17 were phenolics and four were anthocyanin conjugates
(Table 4), and similarly, the cumulative phenolic metabolites
were present at 45-fold higher concentrations (at a range of
2–358 nM at 3 h) than their parent anthocyanins (at a range
of 2–12 nM at 3 h).
The metabolites identified differed substantially be-
tween urine and plasma; plasma contained aldehydes
(4-hydroxybenzaldehyde and 3,4-dihydroxybenzaldehyde),
benzoic acids (4-methoxysalicyclic acid (also known as 2-
hydroxy-4-methoxybenzoic acid) and benzoic acid-4-sulfate)
and methyl derivatives (methyl-3,4-dihydroxybenzoate and
syringic acid), all of which were absent from urine. By com-
parison, urine contained more anthocyanin conjugates (sul-
fate, glucuronide and methyl conjugates), cinnamic acids
(p-courmaric and sinapic acid), phenylacetic acids (homoVA
and homoPCA (also known as 3,4-dihydroxyphenylacetic
acid)), 3,5-dihydroxybenzoic acid and 4-hydroxybenzyl alco-
hol, and all of these conjugates were absent from the plasma
samples.
Anthocyanins reached maximal urinary concentrations of
548 ± 219 nM/mM creatinine 3 h following intake of the
elderberry extract (Table 3). In 3-h post intake urine samples,
C3Gwas present at concentrations of 309± 673 nM/mM cre-
atinine and cyanidin-3-sambubioside was identified at con-
centrations reaching 99 ± 116 nM/mM creatinine. In ad-
dition, nine conjugates of cyanidin were putatively identi-
fied in urine samples: two cyanidin-glucuronides, cyanidin-
diglucuronide, C3G-disulfate, P3G, peonidin-glucuronide
and three P3G-glucuronides, reaching cumulative concen-
trations of 140 ± 33 nM/mM creatinine 3-h post-bolus
(Table 3). Within pooled plasma samples, anthocyanins
reached a maximum concentration of 34 nM 2-h post-
bolus, where C3G and cyanidin-3-sambubioside were present
at concentrations of 7 and 16 nM, respectively. Only two
anthocyanin conjugates, namely cyanidin-glucuronide and
peonidin-glucuronide, were identified within the plasma and
were found at maximum concentrations of 2 and 9 nM at 2-
and 3-h post-bolus, respectively (Table 4).
The maximum cumulative concentration of urinary phe-
nolicmetaboliteswas observed at 3 h,where theywere present
at concentrations of 33 185 ± 2549 nM/mM creatinine, rep-
resenting a 23 448 nM/mM creatinine increase from baseline
values. A high variability was observed in the concentrations
of individual phenolic metabolites, where homoVA and VA
reached the highest concentrations at 3 h, representing lev-
els of 7382 ± 5927 and 4345 ± 3205 nM/mM creatinine,
respectively, while PCA-4-glucuronide and p-courmaric acid
were present in the lowest concentrations, reaching 145 ±
86 and 203 ± 144 nM/mM creatinine, respectively (Table 3).
Within plasma, total concentrations of metabolites cumu-
latively reached 1238 nM, 3-h post-bolus, representing an
847 nM increase from baseline values (Table 4); where PCA-
sulfate reached the highest concentration (358 nM), while
4-methoxysalicyclic acid was identified at the lowest concen-
tration (2 nM) within plasma. Themaximum plasma concen-
tration for the majority of the compounds was at 2 h; how-
ever, PCA, 3,5-dihydroxybenzoic acid, 4-methoxysalicyclic
acid, PCA-4-glucuronide, VA-4-glucuronide, PCA-3-, and 4-
sulfate and benzoic acid-4-sulfate had not reached maximum
concentration by 3 h.
There was no significant difference in the concentra-
tion of metabolites in post-prandial urine collected prior to
(wk 0) and following 12-wk repeated anthocyanin dosing
(Fig. 2).
4 Discussion
To the best of our knowledge, the identified anthocyanin con-
jugates (Tables 3 and 4) represent the largest number of
metabolic conjugates of elderberry anthocyanins identified
to date [24–27]. In addition, despite creatinine adjustment,
the concentration of total anthocyanins quantified in urine
(548 ± 219 nM/mM creatinine) is amongst the highest re-
ported [8,24,28–32]. A total of 28 metabolites were identified
in urine (11 anthocyanin conjugates and 17 phenolic acid
metabolites, Table 3) and 21 in plasma (four anthocyanin
conjugates and 17 phenolic acid metabolites, Table 4). The
most predominant conjugation reaction for anthocyaninswas
glucuronidation, followed by methylation, with many antho-
cyanins undergoing multiple conjugation reactions. Peoni-
din was not present in the elderberry extract and therefore its
identification is indicative of the methylation of cyanidin.
PCA and PGA, the degradation products of C3G, were
detected in both urine and plasma. PCA reached concentra-
tions of 1534 ± 1232 nM/mM creatinine and 24 nM after
3 h in urine and plasma, respectively (Tables 3 and 4). PCA is
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Table 4. Concentration of anthocyanins, anthocyanin conjugates and phenolics in pooled plasma samples following acute anthocyanins
intake (500 mg anthocyanins)
Compound Concentration (nM) (% of total metabolites)a) Previously described
in plasma
Baseline 1 h 2 h 3 h Total
Cyanidin-3-glucosided) ND 4 (0.63) 7 (0.82) 5 (0.38) 16 [18,25]
Cyanidin-3-sambubiosided) ND 10 (1.44) 16 (1.85) 12 (0.91) 38 [18,25]
Cyanidin-glucuronideb),d) ND ND 2 (0.27) 2 (0.18) 5
Peonidin-glucuronidec),d) ND 2 (0.24) 8 (0.96) 9 (0.71) 19
Protocatechuic acid (PCA)d) 11 (2.71) 12 (1.72) 14 (1.65) 24 (1.93) 61 [14,17,18,33]
3,5-Dihydroxybenzoic acidd) 20 (5.05) 18 (2.67) 39 (4.39) 49 (3.92) 126
Vanillic acid (VA)d) 6 (1.64) 35 (5.13) 62 (7.03) 58 (4.60) 161 [14,17,18]
Syringic acidd) 5 (1.16) 17 (2.44) 22 (2.56) 15 (1.20) 59
4-Methoxysalicyclic acidd) 1 (0.23) 0 (0.05) 1 (0.07) 2 (0.13) 3
Methyl-3,4-dihydroxybenzoated) 3 (0.71) 2 (0.33) 6 (0.68) 6 (0.48) 17 [18]
Phloroglucinaldehyded) 4 (1.05) 21 (3.02) 103 (11.69) 72 (5.66) 199 [18]
3,4-Dihydroxybenzaldehyded) 17 (4.43) 18 (2.65) 23 (2.62) 21 (1.68) 80
4-Hydroxybenzaldehyded) 97 (24.74) 146 (21.29) 182 (20.80) 150 (11.85) 575
Ferulic acidd) 8 (1.97) 27 (3.92) 28 (3.23) 21 (1.70) 84 [15,18]
PCA-3-glucuronided) 3 (0.79) 8 (1.10) 15 (1.75) 15 (1.22) 41 [18]
PCA-4-glucuronided) 6 (1.43) 4 (0.52) 10 (1.14) 14 (1.11) 33 [18]
IsoVA-3-glucuronided) 10 (2.65) 14 (1.97) 24 (2.71) 22 (1.71) 69
VA-4-glucuronided) 16 (4.21) 33 (4.85) 78 (8.91) 120 (9.49) 248
PCA-sulfated),e) 92 (23.55) 74 (10.78) 115 (13.17) 358 (28.31) 640 [18]
VA-sulfated),f) 27 (6.79) 161 (23.43) 23 (2.67) 93 (7.36) 304 [18]
Benzoic acid-4-sulfated) 66 (16.89) 81 (11.82) 97 (11.02) 196 (15.48) 439
Total anthocyanins ND 16 34 28 78
Total phenolic metabolites 391 670 842 1238 3140
2-, 3- and 4-hydroxybenzoic acid, benzoic acid-4-glucuronide and hippuric acid were identified but showed no increase from baseline
concentrations.
a) Values represent concentrations of a pooled sample (n = 1) from the samples of 15 participants, with percentage of total metabolites
across each timepoint represented in brackets.
b) No standard available, quantified relative to cyanidin-3-glucoside.
c) No standard available, quantified relative to peonidin-3-glucoside.
d) Visual increase in concentration compared to baseline values (no statistical analysis possible as a result of using a pooled sample).
e) PCA-3-sulfate co-elutes with PCA-4-sulfate and concentrations represent the combined total.
f) Vanillic acid-4-sulfate co-elutes with isovanillic acid-3-sulfate and concentrations represent the combined total.
PCA, protocatechuic acid; ND, not detected; VA, vanillic acid.
naturally present in many fruits, including elderberries, and
in the present study was the most abundant phenolic in the
intervention foods, present at concentrations of 138.59 mg/g
extract (Table 2). The presence of PCA in the background diet
may have therefore led to an overestimation of anthocyanin-
derived PCA in this and previous interventions [12–14].
PGA was identified at maximum concentrations of 602 ±
632 nM/mM creatinine at 3 h and 103 nM at 2 h in urine
(Table 3) and plasma (Table 4), respectively. To the best of
our knowledge, this is the first study where PGA has been
identified in human blood or urine following a fruit-derived
anthocyanin intervention.
The degradation products of anthocyanins appeared to
undergo further phase I and II metabolism as apparent by
the identification of various methylated (VA), glucuronidated
(PCA-3-glucuronide, PCA-4-glucuronide, VA-4-glucuronide
and isoVA-3-glucuronide), sulfated (PCA-sulfate and
VA-sulfate) and de/hydroxylated (4-hydroxybenzoic acid
and 3,5-dihydroxybenzoic acid) products. VA-4-glucuronide
demonstrated the largest increase from baseline values in
urine, reaching concentrations of 2296 ± 946 nM/mM crea-
tinine 3-h post-bolus (Table 3) and PCA-sulfate demonstrated
the largest increase in concentration in plasma, reaching
358 nM 3 h following intake (Table 4). 4-Hydroxybenzoic
acid and VA have previously been identified within biological
samples following bilberry-lingonberry pure´e [13], cranberry
juice [15] and strawberry consumption [33], while to the best
of our knowledge, the glucuronidated and sulfated metabo-
lites of PCA, VA and hydroxybenzoic acid have not been
previously identified following a fruit-derived anthocyanin
intervention. Anthocyanins also appeared to be metabolised
to phenylpropenoic, phenylacetic and phenylalcohol struc-
tures, as homoVA, homoPCA, 4-hydroxybenzyl alcohol, p-
courmaric acid, ferulic acid and sinapic acid were established
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 2. Baseline (BL) and post-bolus (0–3 h) anthocyanin and metabolite concentrations in urine. (A) Concentration of major antho-
cyanin metabolites (>8 M/mM creatinine) identified following a single bolus and (B) following 12-wk supplementation; (C) concentration
of minor anthocyanin metabolites (<8 M/mM creatinine) identified following a single bolus and (D) following 12-wk supplementation;
metabolites are classified by conjugation/structure where hydroxybenzoic acids include 4-hydroxybenzoic acid, protocatechuic acid (PCA),
3,5-dihydroxybenzoic acid, vanillic acid (VA), PCA-3-glucuronide, PCA-4-glucuronide, VA-4-glucuronide, isoVA-3-glucuronide, PCA-sulfate
and VA-sulfate; methyl conjugates include VA, homoVA, ferulic acid, sinapic acid, VA-4-glucuronide, isoVA-3-glucuronide and VA-sulfate;
phenylacetic acids include homoPCA and homoVA; phenylpropenoic acids include p-courmaric acid, ferulic acid and sinapic acid; an-
thocyanins include cyanidin-3-glucoside (C3G), cyanidin-3-sambubioside, cyanidin-glucuronides, cyanidin-diglucuronide, C3G-disulfate,
peonidin-3-glucoside (P3G), peonidin-glucuronide and P3G-glucuronides; phenylaldehydes include phloroglucinolaldehyde; phenylalco-
hols include 4-hydroxybenzyl alcohol; glucuronide conjugates include PCA-3-glucuronide, PCA-4-glucuronide, VA-4-glucuronide and isoVA-
3-glucuronide; and sulfate conjugates include PCA-sulfate and VA-sulfate.
to increase from baseline concentrations in post-prandial
urine samples (Table 3). Similarly, syringic acid, 4-
methoxysalicyclic acid, methyl-3,4-dihydroxybenzoate, 3,4-
dihydroxybenzaldehyde, 4-hydroxybenzaldehyde and ferulic
acid were detected at increased concentrations in post-
prandial plasma samples (Table 4). Of these, homoVA, ho-
moPCA, p-courmaric acid, ferulic acid and sinapic acid have
been previously detected within urine [13,14], and ferulic acid
has previously been identified within plasma [15] following
anthocyanin interventions feeding phenolic-rich products.
The phenylacetic structures, homoVA and homoPCA,
which together provided a 4762 nM/mM creatinine in-
crease from baseline urinary levels, appeared to be ma-
jor anthocyanin metabolites in urine but were absent
from plasma. Similarly, p-courmaric acid, sinapic acid, 3,5-
dihydroxybenzoic acid and 4-hydroxybenzyl alcohol were also
identified within urine, but were absent from the plasma.
The presence of metabolites in the urine but not the plasma
suggests some compounds were below the detection limit of
the methodology but became detectable as they were concen-
trated by the kidneys and excreted into the urine.
The plasma contained 4-hydroxybenzaldehyde, 3,4-
dihydroxybenzaldehyde, 4-methoxysalicyclic acid, benzoic
acid-4-sulfate, methyl-3,4-dihydroxybenzoate and syringic
acid, which were absent from urine samples. The appearance
ofmetabolites in the plasma but not in the urine suggests that
somemetabolites may have been metabolised further in vari-
ous tissues, or were eliminated by the biliary route, and either
metabolised further by colonic bacteria and reabsorbed or ex-
creted. This is supported by the identification of methyl-3,4-
dihydroxybenzoate and 4-methoxysalicyclic acid within faecal
samples following our recent 13C-C3G study [18]. Conjugates
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of phenolic degradation products of anthocyanins appear in
the circulation as early as 1-h post-consumption (Table 4) [18],
suggesting they do not follow the commonly reported elim-
ination profiles of other flavonoids, such as quercetin and
epicatechin, which require bacterial catabolism to liberate
free phenolic intermediates, and therefore appear much later
in the circulation [6,34–38]. The early appearance of phenolic
metabolites in the present study likely results from the insta-
bility of anthocyanins at physiological pH (pH5–7) [10,11,38],
resulting in their rapid degradation and metabolism within
the proximal and distal small intestine. In addition, the pres-
ence of bacteria within the small intestine will also contribute
to the appearance of these metabolites [39].
In the present study, a number of unconjugated metabo-
lites, including PCA, p-courmaric acid and homoPCA, were
identified. Although flavonoids are generally reported in the
circulation as conjugatedmetabolites [40], unconjugated phe-
nolic acids have been reported at levels similar to those de-
tected within the present intervention study [13, 14, 18].
Several other putative phenolic metabolites were explored
(such as hippuric acid, 2-, 3- and 4-hydroxybenzoic acid and
benzoic acid-4-glucuronide) as they have been previously re-
ported as possible anthocyanin- or flavonoid-derived metabo-
lites [13–15, 18, 33]; however, these compounds were not
shown to increase in concentration frombaseline levels in the
present study, and are therefore likely predominantly derived
from other source in the “background” diet or endogenous
protein turnover [41]. Anthocyanin metabolismmay however
contribute to their concentrations in biofluids to some extent.
The present study is the first study to the best of our
knowledge to look at post-prandial phenolic metabolite ex-
cretion following sustained anthocyanin intake. A previous
flavonoid intervention found that daily quercetin supplemen-
tation over 2 wk resulted in increased plasma quercetin con-
centrations [42], suggesting reduced clearance following re-
peated dosing. However, there was no significant impact of
12-wk daily intake of anthocyanins on urinary metabolite ex-
cretion in the present investigation (Fig. 2). This is in accor-
dance with a previous 8-wk berry intervention that found no
effect of sustained dosing on fasting polyphenol concentra-
tions [17], which suggests there is little risk of bioaccumula-
tion or toxicity associated with the metabolism and clearance
of anthocyanins. There was an increase in plasma antho-
cyanins (78 nM at wk 0 versus 100 nM at wk 12) and decrease
in hydroxybenzoic acids (3 nM at wk 0 versus 2 nM at wk 12)
following sustained dosing (Fig. 3); however, no statistical
comparisons were possible due to the use of pooled plasma
samples (n = 1). This observation was not apparent in the
urine analysis.
In contrast to our recent intervention study where we
fed pure, 13C-labeled synthetic C3G [18], here we adminis-
tered a dose that more closely mimics a dietary source of
anthocyanins, such as that found in a single serving of some
berries [19, 21]. While the present study therefore provides a
comprehensive account of the metabolism of anthocyanins
following acute and chronic consumption of elderberries,
there are certain limitations with this work. Primarily, al-
though the use of a food source of anthocyanins, as opposed
to a pure chemical, better represents habitual dietary intake, it
complicates the elucidation of anthocyanin-derived metabo-
lites.
Phenolic compounds are ubiquitous within plants [43,44]
and are present in quantities of 0.04–138.59 mg/g within the
elderberry extract (Table 2) and breakfast provided. As the
intervention meal was fed ad libitum, and intakes were not
reported, the phenolic intake could not be quantitatively es-
tablished with accuracy. However, database analysis of the
main ingredients present within the breakfast (unprocessed
wheat, barley and maize) indicated that the foods likely con-
tained six of the metabolites identified in the present study,
at concentrations ranging from 0.01 to 0.15 mg/100 g FW
[21], presuming the phenolics are not degraded during pro-
cessing. In addition, some of the metabolites identified in
the present study are typically associated with the colonic
metabolites of other phenolic compounds [11] and could
therefore be derived from prior consumption of a range of
polyphenolic compounds other than anthocyanins. For ex-
ample, propenoic acids and phenylacetic acids are reported
metabolites of flavonols and procyanidins [34, 45]. However,
only metabolites that increased from fasted/baseline levels
were reported presently and in addition, 19 and 11 of the
metabolites identified in urine and plasma, respectively, in-
cluding ferulic acid and phase II conjugates of PCA and VA,
were recently reported in a 13C-labeled anthocyanin feeding
study [18]. Together this suggests that the metabolites iden-
tified within the present study were derived, at least in part,
from the consumed anthocyanins. Nevertheless, without the
use of a labeled anthocyanin, it is not possible to categorically
define the origin of all phenolics within the diet, and there-
fore the contribution of phenolic acids from other sources
consumed prior to the fast cannot be definitively excluded.
The samples collected in the present study were limited to
3-h post-bolus sampling, and longer duration sampling fol-
lowing acute exposure would have allowed us to conduct a
more comprehensive pharmacokinetic analysis. In addition,
there are a number of substances known to interfere with
the creatinine assay [46]; however, we found no reports in the
literature of anthocyanins interfering with creatinine mea-
surements. Anthocyanins do absorb at the same wavelength
as the assay substrate (510/570 nm), however theywould have
minimal absorbance intensity under the alkaline conditions
of the assay [47] and are therefore likely to have minor im-
pact on assay sensitivity. The collection and measurement of
complete urine voids would have allowed total recoveries to
be calculated as opposed to reporting creatinine-adjusted con-
centrations. Finally, as polyphenol metabolites are generally
more concentrated in the urine, and urinary clearance gener-
ally reflects the circulating plasma pool of polar metabolites,
plasma samples were pooled to reduce analytical costs. This
may be seen as a further limitation of the present analysis
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Figure 3. Baseline (BL) and post-bolus (0–3 h) anthocyanin and metabolite concentrations in plasma. (A) Concentration of major antho-
cyanin metabolites (>150 nM) identified following a single bolus and (B) following 12-wk supplementation; (C) concentration of minor an-
thocyanin metabolites (<150 nM) identified following a single bolus and (D) following 12-wk supplementation; metabolites are classified by
conjugation/structure where hydroxybenzoic acids include protocatechuic acid (PCA), 3,5-dihydroxybenzoic acid, vanillic acid (VA), syringic
acid, 4-methoxysalicyclic acid, PCA-3-glucuronide, PCA-4-glucuronide, VA-4-glucuronide, isoVA-3-glucuronide, PCA-sulfate and VA-sulfate;
methyl conjugates include VA, syringic acid, 4-methoxysalicyclic acid, methyl-3,4-dihydroxybenzoate, ferulic acid, VA-4-glucuronide, isoVA-
3-glucuronide and VA-sulfate; phenylaldehydes include phloroglucinaldehyde, 4-hydroxybenzaldehyde and 3,4-dihydroxybenzaldehyde;
glucuronide conjugates include PCA-3-glucuronide, PCA-4-glucuronide VA-3-glucuronide and isoVA-3-glucuronide; sulfate conjugates
include PCA-sulfate, VA-sulfate and benzoic acid-4-sulfate; anthocyanins include cyanidin-3-glucoside, cyanidin-3-sambubioside, cyanidin-
glucuronide and peonidin-glucuronide; cinnamic acids include ferulic acid; and benzoates include methyl-3,4-dihydroxybenzoate.
as it reduces the intrinsic variability in clearance kinetics be-
tween participants. In order to determine whether there was
an increase in anthocyanin recovery and decrease in hydrox-
ybenzoic acid recovery following sustained dosing (Fig. 3),
the present study would need to have analysed participant
samples individually.
In conclusion, the present study identified a greater num-
ber of anthocyanin metabolites and higher metabolite con-
centrations than previously reported, with phenolic metabo-
lites identified at 60- and 45-fold higher concentrations than
their parent compounds in urine and plasma, respectively. No
significant difference in metabolism or clearance was identi-
fied following chronic anthocyanin consumption, suggesting
there is no alteration inmetabolic processing following 12 wk
intake versus acute exposure. These results therefore indicate
that anthocyanins degrade and are extensively metabolised in
vivo, suggesting that the accumulation of multiple phenolic
metabolites may ultimately be responsible for the reported
bioactivity of anthocyanins.
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